In BC patients, about 70% of HER2 mutations have been found in metastatic ER+/HER2 non-amplified tumors, suggesting that the emergence of HER2 mutations may represent a mechanism of acquired resistance to endocrine therapy (69). This evidence concerns the gene ERBB2 and breast cancer.